TriSalus Life Sciences Stock (NASDAQ:TLSI)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$4.46

52W Range

$3.32 - $10.42

50D Avg

$4.39

200D Avg

$7.00

Market Cap

$137.21M

Avg Vol (3M)

$47.74K

Beta

0.50

Div Yield

-

TLSI Company Profile


TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

107

IPO Date

Feb 08, 2021

Website

TLSI Performance


TLSI Financial Summary


Dec 23Dec 22Dec 21
Revenue$18.51M$12.40M$8.40M
Operating Income$-54.15M$-36.44M$-24.03M
Net Income$-59.04M$-47.19M$-28.84M
EBITDA$-53.40M$-44.59M$-22.82M
Basic EPS-$-1.79$-1.10
Diluted EPS-$-1.79$-1.10

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 15, 24 | 2:33 PM
Q1 24May 15, 24 | 11:40 AM
Q4 23Apr 01, 24 | 10:56 AM